NASDAQ · ENSC
Healthcare · Biotechnology
$0.45
Down-$0.03 (-6.19%)
Updated Sep 16, 2026, 12:01 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ENSC closed at $0.45 after 20 trading sessions, up 17.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.4757 | $0.4758 | $0.4404 | $0.4516 | 320.14K |
| Sep 14, 2026 | $0.49 | $0.505 | $0.473 | $0.4814 | 425.14K |
| Sep 11, 2026 | $0.52 | $0.523 | $0.4769 | $0.4869 | 562.95K |
| Sep 10, 2026 | $0.477 | $0.5257 | $0.44 | $0.5159 | 940.38K |
| Sep 9, 2026 | $0.48 | $0.4979 | $0.4606 | $0.4744 | 680.58K |
| Sep 8, 2026 | $0.47 | $0.4988 | $0.401 | $0.473 | 1.45M |
| Sep 4, 2026 | $0.44 | $0.459 | $0.412 | $0.4557 | 550.36K |
| Sep 3, 2026 | $0.4361 | $0.4517 | $0.4276 | $0.44 | 441.01K |
| Sep 2, 2026 | $0.40 | $0.4475 | $0.3771 | $0.4428 | 1.4M |
| Sep 1, 2026 | $0.3851 | $0.3947 | $0.377 | $0.3881 | 209.32K |
| Aug 31, 2026 | $0.39 | $0.4104 | $0.385 | $0.3927 | 528.48K |
| Aug 28, 2026 | $0.4048 | $0.4119 | $0.385 | $0.3999 | 490.89K |
| Aug 27, 2026 | $0.40 | $0.4099 | $0.39 | $0.399 | 572.28K |
| Aug 26, 2026 | $0.41 | $0.4173 | $0.3905 | $0.412 | 747.45K |
| Aug 25, 2026 | $0.361 | $0.4164 | $0.355 | $0.403 | 1.7M |
| Aug 24, 2026 | $0.3734 | $0.3734 | $0.3536 | $0.361 | 966.71K |
| Aug 21, 2026 | $0.3705 | $0.3745 | $0.3624 | $0.3733 | 778.16K |
| Aug 20, 2026 | $0.3803 | $0.3872 | $0.3603 | $0.3778 | 911.11K |
| Aug 19, 2026 | $0.369 | $0.39 | $0.3681 | $0.388 | 1.56M |
| Aug 18, 2026 | $0.396 | $0.4055 | $0.3618 | $0.385 | 2.92M |
The latest Smart Investors Daily articles mentioning ENSC.
ENSC research
Company profile and research snapshot.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2023 | HC Wainwright & Co. | Buy | — |
| Jul 3, 2023 | HC Wainwright & Co. | Buy | — |
| Nov 17, 2022 | Lake Street | Buy | — |
| Nov 30, 2021 | Lake Street | Buy | — |
No generated briefing is available yet.
Yahoo · Mar 4, 2026
~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...
Benzinga · Mar 3, 2026
Yahoo · Mar 3, 2026
~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), ...
Benzinga · Mar 3, 2026
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENSC.
